Eaton Vance Worldwide Health Sciences is a solid source of global healthcare exposure, rather than a superior one.
Eaton Vance Worldwide Health Sciences Fund Class A ETHSX
- NAV / 1-Day Return 12.53 / −0.88 %
- Total Assets 757.9M
-
Adj. Expense Ratio
1.180%
- Expense Ratio 1.170%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Value
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.55%
- Turnover 30%
USD | NAV as of Jun 17, 2026 | 1-Day Return as of Jun 17, 2026, 10:53 PM GMT+0
Morningstar’s Analysis ETHSX
Will ETHSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the ETHSX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of ETHSX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 10.53 | 80M | Healthcare |
Johnson & Johnson | 6.56 | 50M | Healthcare |
AstraZeneca PLC | 6.37 | 48M | Healthcare |
AbbVie Inc | 6.25 | 47M | Healthcare |
UnitedHealth Group Inc | 5.33 | 41M | Healthcare |
Roche Holding AG | 5.26 | 40M | — |
Bristol-Myers Squibb Co | 4.50 | 34M | Healthcare |
Merck & Co Inc | 4.42 | 34M | Healthcare |
Gilead Sciences Inc | 3.24 | 25M | Healthcare |
Vertex Pharmaceuticals Inc | 3.22 | 24M | Healthcare |
United States